Navigation Links
NeurogesX Reports First Quarter 2009 Results
Date:5/7/2009

Conference Call Scheduled Today at 4:30pm ET

European Commission Decision on Qutenza(TM) Expected in 1H 2009

Company to Provide Update on FDA review of Qutenza During Conference Call Today

Corporate Highlights:

- CHMP issued positive opinion recommending approval of Qutenza(TM) (formerly NGX-4010) for treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain

Upcoming 2009 Milestones:

- European Commission decision on MAA for Qutenza anticipated first half of 2009

- European commercial partnership for Qutenza targeted first half of 2009

- FDA PDUFA date of August 16, 2009 for Qutenza NDA to manage pain associated with PHN

SAN MATEO, Calif., May 7 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for the first quarter ended March 31, 2009 and provided an update on recent developments.

During the first quarter of 2009, NeurogesX continued to focus on seeking regulatory approvals and on pre-commercialization activities for its lead product candidate Qutenza (formerly NGX-4010). On March 19, 2009, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending approval of the marketing authorization application (MAA) for Qutenza for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain.

The CHMP's recommendation for the MAA, filed under the centralized procedure, is
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
2. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
3. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
4. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
5. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
6. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
7. NeurogesX Reports Third Quarter 2008 Results
8. NeurogesX to Report Third Quarter 2008 Financial Results
9. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
10. NeurogesX Responds to EMEAs Day 120 Questions
11. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)..., , NOVATO, Calif., Nov. 30 /PRNewswire-Firs...MRN ) announced today that the Food and Drug Admin...n for 3,4-diaminopyridine (3,4-DAP), amifampridine...t Eaton Myasthenic Syndrome (LEMS). 3,4-DAP has p...E.U. Also, in October 2009, the Committee for Med...
(Date:11/30/2009)..., , BOSTON and COPENHAGEN, Nov. 30 /PRNew...) announced today that the Harvard Medical School ... recognized as a MicroRNA Screening Center of Exce...Medical School, and associated hospitals and insti...lecule and RNAi libraries. ,, MicroRNAs are a n...
(Date:11/30/2009)..., , AMSTERDAM,...he world,s,leading publisher of scientific, medica...nced a major re-launch of Embase, its comprehensiv...indexed records from more than 7,000,active, peer ...ed a key role in the advancement of new biomedical...
(Date:11/27/2009)..., , DURHAM, N.C., Nov. 27 /PRNewswire...k, will initiate water-soluble carbon nanotube-bas.... The water-soluble carbon nanotubes, which have f...ugation with cancer drugs, was developed in partne...he conjugated carbon nanotubes serves as a drug de...
Breaking Biology Technology:FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 2Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 3North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2
...assay for inhibition of poly(ADP-ribose) polymeras...es the inhibition of PARP-activated incorporation ...NAD). The incorporation is detected using Europium...way to screen test compounds for PARP activity in ...reening. , Poly(ADP-ribose) polymerase (PA...
...ts (QDs) have potential applications, ...emory devices, and sources of laser ..., herein to possess a nonlinear change ...correlated to size and composition, as monitored b...pectrofluorometer. The QDs, emission wavelength,...
... Many companies claim high sensitivity for their ...rument vendors often cite excitation of de-ionized...at 397 nm (an energy loss of 3380 cm 1 ). This Ram...nal is red-shifted and weak, thus mimicking weak f...making sample-to-sample reproducibility straightfo...
Other Biology Technology:A DELFIA Assay for Inhibition of PARP 2A DELFIA Assay for Inhibition of PARP 3Photoluminescence Spectroscopy of Quantum Dots, monitored by the Spex FluoroMax 2Photoluminescence Spectroscopy of Quantum Dots, monitored by the Spex FluoroMax 3Photoluminescence Spectroscopy of Quantum Dots, monitored by the Spex FluoroMax 4Wideband sensitivity of the FluoroLog-3 2
(Date:12/1/2009)...s an ,abominable mystery, and it is a question whi... when did flowering plants evolve and how did they...dy in Ecology Letters reveals the evolutionary t... a major competitive advantage over rival species,..., The study, by Dr Tim Brodribb and Dr Taylor Fi...
(Date:11/30/2009)... review of the state of Antarctica,s climate and i...blished this week (Tuesday 1 December) by the Scie...e review - Antarctic Climate Change and the Enviro...ontinent, identifies areas for future scientific r...olicy makers have about Antarctic melting, sea-lev...
(Date:11/30/2009)...of Pittsburgh team overcame a major hurdle plaguin...hat could lead to more efficient catalysts used to...c. The researchers reported Nov. 29 in Nature Mat...e stability in metallic nanoparticles, the vaunted...lity to extreme heat. , Gtz Veser, an associate ...
Breaking Biology News(10 mins):How did flowering plants evolve to dominate Earth? 2First comprehensive review of the state of Antarctica's climate 2First metallic nanoparticles resistant to extreme heat 2Sherman Oaks Hospital Opens New Cardiac Catheterization Laboratory and Reopens Behavioral Health Facility for Seniors 55349 1Sherman Oaks Hospital Opens New Cardiac Catheterization Laboratory and Reopens Behavioral Health Facility for Seniors 55349 2Sherman Oaks Hospital Opens New Cardiac Catheterization Laboratory and Reopens Behavioral Health Facility for Seniors 55349 3Iowa Drug Card a Huge Success With Iowans 55345 1Iowa Drug Card a Huge Success With Iowans 55345 2Burner Balm Responds to Barrage of UK Protests Over New Lip Balm 55340 1Burner Balm Responds to Barrage of UK Protests Over New Lip Balm 55340 2
... MADISON Pfizer Inc., a major biopharmaceutical ...ion (WARF), the private, nonprofit patenting and l...sin-Madison, announced May 5 that they have signed...ents for the development of new drug therapies. , ...rk with hES cells for drug research and discovery....
... , An effort is under way at the University of Hou...obile industry to develop new tools that will help...rapy for patients with head and neck cancer. , Dr... Free Form Fabrication Laboratory at UH and a form.... Lei Dong, associate professor and deputy researc...
... The National Center for Research Resources (NCRR...unced today it will provide up to an estimated $12...tional Development Award (IDeA) Networks of Biomed...gible states. By promoting the development, coordi...tise, these awards expand research opportunities a...
Other Biology News:WARF signs license agreement with Pfizer for human embryonic stem cells 2From cars to cancer: UH professor employs auto industry tools for tumor therapy 2From cars to cancer: UH professor employs auto industry tools for tumor therapy 3From cars to cancer: UH professor employs auto industry tools for tumor therapy 4NIH grants $122 million in Institutional Development Awards 2NIH grants $122 million in Institutional Development Awards 3
Anti-IRS 2, phospho (Ser731) Polyclonal Antibody, Unconjugated from BioSource International (Invitrogen)
... for non-denaturing polyacrylamide and agarose gel... solution contains a bromophenol blue tracking dye...loading. EDTA has been included to inhibit nucleas...added to help dissociate DNA-protein complexes whi...
Gel Loading Solution (Type I) from Sigma-Aldrich
Mouse Anti-Human QPRT Polyclonal Antibody, Unconjugated from Novus Biologicals
Biology Products: